Capricor Therapeutics (CAPR) late Wednesday reported a Q3 net loss of $0.38 per diluted share compared with a loss of $0.25 a year earlier.
Analysts polled by Capital IQ expected a loss of $0.36.
Revenue for the quarter ended Sept. 30 was $2.3 million, compared with $6.2 million a year earlier.
Analysts expected $3.6 million.
The biotechnology company finished the quarter with around $85 million in cash and equivalents, which it said would fund its anticipated expenses into 2027.
Price: 16.05, Change: -0.86, Percent Change: -5.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。